The $11.6 billion deal for Bioverativ would bolster the French pharmaceutical giant’s portfolio as it faces falling sales for its diabetes drug, Lantus.

from Health http://ift.tt/2Dusfn4

0 comments:

Post a Comment

Popular Posts